îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
Harrow Inc
HROWîāđāļāļīāđāļĄāļĨāļāđāļāļĢāļēāļĒāļāļēāļĢāļāļīāļāļāļēāļĄ
33.080USD
-0.050-0.15%
āļāļīāļÂ 09-17 16:00ïžETïž
1.24BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
āļŦāļĨāļąāļāļāļĨāļēāļāļāļīāļÂ 17:04Â (ET)33.300USD+0.250+0.76%
āļŦāļĨāļąāļāļāļĨāļēāļāļāļīāļÂ 17:04Â (ET)āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Harrow Inc āļāļĢāļīāļĐāļąāļ
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc āđāļāļĢāđāļāļĨāđ
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļHROW
āļāļ·āđāļāļāļĢāļīāļĐāļąāļHarrow Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 08, 2013
āļāļĩāļāļĩāđāļMullery (Frank)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ382
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 08
āļāļĩāđāļāļĒāļđāđ1A Burton Hills Blvd
āđāļĄāļ·āļāļNASHVILLE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ37215
āđāļāļĢāļĻāļąāļāļāđ16157334731
āđāļ§āđāļāđāļāļāđhttps://www.harrow.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļHROW
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 08, 2013
āļāļĩāļāļĩāđāļMullery (Frank)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Harrow Inc
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
āļāļģāļāļēāļĄāļāļĩāđāļāļāļāđāļāļĒ
āđāļāļĢāļāļ·āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Harrow Inc?
îāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Harrow Inc āđāļāđāđāļāđ: Mr. Mark L. Baum, J.D.
āļĄāļĩāļāļĩāđāļŠāļāļēāļāļąāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Harrow Inc (HROW)?
îāļ āļ§āļąāļāļāļĩāđ 2026Q1 āļĄāļĩāļŠāļāļēāļāļąāļāļāļģāļāļ§āļ 418 āđāļŦāđāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Harrow Inc āđāļāļĒāļĄāļĩāļĄāļđāļĨāļāđāļēāļĢāļ§āļĄāļāļĢāļ°āļĄāļēāļ 24.67M āļāļīāļāđāļāđāļ 66.17% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ āđāļĄāļ·āđāļāđāļāļĩāļĒāļāļāļąāļāļ§āļąāļāļāļĩāđ 2025Q4 āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļāđāļāđāđāļāļīāđāļĄāļāļķāđāļ 347374.00